Heron Therapeutics, Inc.
- Heron Therapeutics Announces FDA Approval of an Indication Expansion for Zynrelef for Postoperative Pain Management - December 9, 2021
- Heron Therapeutics Announces Submission of HTX-019 NDA for the Prevention of Postoperative Nausea and Vomiting to FDA - November 18, 2021
- FDA Approves Zynrelef (bupivacaine and meloxicam) for the Management of Postoperative Pain - May 13, 2021
- Heron Therapeutics Announces Publication of Results from EPOCH 1 Follow-On Study of HTX-011 in Patients Undergoing Bunionectomy Surgery - January 21, 2021
- Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Treatment of Postoperative Pain - November 13, 2020
- Heron Therapeutics Receives Complete Response Letter for HTX-011 for the Management of Postoperative Pain - June 29, 2020
- Heron Therapeutics Announces FDA Extension of Review Period for NDA for HTX-011 for the Management of Postoperative Pain - February 19, 2020
- Heron Therapeutics Announces FDA Acceptance of New Drug Application Resubmission for HTX-011 for Management of Postoperative Pain - October 28, 2019
- FDA Approves Supplemental New Drug Application to Expand Cinvanti (aprepitant) Label for Single-Dose Regimen for Patients Receiving Moderately Emetogenic Chemotherapy (MEC) - October 22, 2019
- Heron Therapeutics Resubmits New Drug Application to FDA for HTX-011 for the Management of Postoperative Pain - October 1, 2019
Drugs Associated with Heron Therapeutics, Inc.
Heron Therapeutics, Inc. manufactures, markets and/or distributes more than 3 drugs in the United States. Medications listed here may also be marketed under different names in different countries. Non-US country and region specific information is not available on this page.
Generic name: aprepitant
Drug class: NK1 receptor antagonists
Generic name: granisetron
Drug class: 5HT3 receptor antagonists
|1 review||1.0 / 10|
Generic name: bupivacaine/meloxicam
Drug class: analgesic combinations
|For ratings, users were asked how effective they found the medicine while considering positive/adverse effects and ease of use (1 = not effective, 10 = most effective).|